Laparoscopic Adjustable Gastric Banding With Truncal Vagotomy
| Status: | Archived |
|---|---|
| Conditions: | High Blood Pressure (Hypertension), High Cholesterol, Insomnia Sleep Studies, Obesity Weight Loss, Overactive Bladder, Pulmonary, Diabetes, Urology, Metabolic |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Endocrinology, Gastroenterology, Nephrology / Urology, Pharmacology / Toxicology, Psychiatry / Psychology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
Pilot Study Assessing Advantage of Adding Truncal Vagotomy to LAGB
Laparoscopic Adjustable Gastric Banding (LAGB) is a gold standard in the surgical treatment
of morbid obesity. We hypothesize that the addition of truncal vagotomy (cutting of nerves
to the stomach) will produce greater weight loss and better reduction of co-morbidities
(diseases caused by or aggravated by morbid obesity) than LAGB alone. 25 patients will be
enrolled and outcomes compared to LAGB historical controls over a post-operative period of
24 months.
The patients will receive standard laparoscopic adjustable gastric banding treatment as
well as truncal vagotomy. The vagus nerves will be cut just below the diaphragm using the
same access ports that are used during the laparoscopic adjustable gastric banding. During
the surgical procedure, the first fifteen patients will also receive a dose of Baclofen, a
vagus nerve stimulant, and an endoscopy at the end of the procedure during which congo red
dye will sprayed within the stomach. The Baclofen and endoscopy are used to ensure that all
branches of the vagus nerve have been cut. If, after 15 complete vagotomies, are verified by
the above testing then the use of Baclofen and endoscopy will be abandoned.
We found this trial at
1
site
Click here to add this to my saved trials
